The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders. In comments submitted to the committee, AHA said, “For 25 years, the 340B program – which enjoys broad, bipartisan support – has been critical in helping hospitals expand access to lifesaving prescription drugs and comprehensive health care services to low-income and uninsured individuals in communities across the country. In addition, the AHA and its member hospitals support program integrity efforts to ensure that the 340B program remains available to safety-net providers. We have worked and continue to work with [HRSA] and its partners on these efforts.” In addition, the AHA voiced support for the Closing Loopholes for Orphan Drugs Act (H.R. 2889), legislation that would allow 340B-eligible hospitals subject to the orphan drug exclusion to purchase “orphan drugs” through the program when the drugs are used to treat an illness other than the rare conditions for which the designation was given. The AHA also expressed deep concerns over the Centers for Medicare & Medicaid Services’ recently released hospital outpatient prospective payment system proposed rule for calendar year 2018, which would drastically cut Medicare payment for drugs acquired under the 340B program.

Related News Articles

Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The Census Bureau reported (https://www2.census.gov/library/publications/2025/demo/acsbr-024.pdf) that the uninsured rate increased nationally to 8.2% in 2024…
Perspective
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
The Centers for Medicare & Medicaid Services Sept. 9 issued preliminary guidance regarding the implementation of certain state-directed payment provisions…
Headline
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…